Ma Xiaocong, Tang Meiwen, Lu Liying, Zheng Jinghui, Huang Jingjing, Li Junhong, Luo Weisheng
Graduate School, Guangxi University of Chinese Medicine.
Department of Geriatrics, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine.
Medicine (Baltimore). 2020 Jul 10;99(28):e21036. doi: 10.1097/MD.0000000000021036.
Liver fibrosis is a pathological change existing in most chronic liver diseases, which leads to abnormal changes in liver tissue structure and affects the normal physiological function of liver. Without effectively control, liver fibrosis can develop into cirrhosis and increase the risk of liver cancer. Salvianolic acid B (Sal B) is the main active component in the water-soluble extract from Salvia miltiorrhiza, which is a traditional Chinese medicine usually used for treating cardiovascular and liver diseases. It is reported that Sal B shown a good action against liver fibrosis via numerous signaling pathways, which indicate that Sal B is a potential candidate drug for the treatment of liver fibrosis.
We searched the related researches from the following electronic databases: PubMed, EMBASE, Web of science, China National Knowledge Infrastructure (CNKI), China Biology Medicine (CBM), Wan fang Database for Chinese Technical Periodicals and VIP Database. All the databases were searched from inception to December 2019. No restriction of language, publication date, or publication status. PICO of this systematic review are shown as flowing: P, preclinical studies which evaluated the effects of Sal B on the animal models of liver fibrosis with controlled studies; I, received Sal B as only treat in any dose; C, received normal saline, distilled water, or no treatment; O, the primary outcome include measure will be the decrease in liver fibrosis score, and the secondary outcomes include the index of liver fibrosis. All the included data will be analyzed with the software of Review Manager 5.2 and STATA 14.2.
The purpose of this study is to conduct a systematic review and meta-analysis to assess the effects on anti-liver fibrosis of Sal B, and this will be contribute to drug development and pathological mechanisms of clinical research.
INPLASY202050101, registered on 28/5/2020.
肝纤维化是大多数慢性肝病中存在的一种病理变化，它会导致肝组织结构异常并影响肝脏的正常生理功能。若不有效控制，肝纤维化可发展为肝硬化并增加患肝癌的风险。丹酚酸B（Sal B）是丹参水溶性提取物中的主要活性成分，丹参是一种常用于治疗心血管疾病和肝脏疾病的传统中药。据报道，Sal B通过多种信号通路对肝纤维化显示出良好的作用，这表明Sal B是治疗肝纤维化的潜在候选药物。
我们从以下电子数据库检索相关研究：PubMed、EMBASE、科学网、中国知网（CNKI）、中国生物医学文献数据库（CBM）、万方中国科技期刊数据库和维普数据库。所有数据库从建库至2019年12月进行检索。不限制语言、出版日期或出版状态。本系统评价的PICO如下：P，评估Sal B对肝纤维化动物模型影响的对照研究的临床前研究；I，接受任何剂量的Sal B作为唯一治疗；C，接受生理盐水、蒸馏水或未治疗；O，主要结局指标将是肝纤维化评分的降低，次要结局指标包括肝纤维化指标。所有纳入的数据将使用Review Manager 5.2和STATA 14.2软件进行分析。
本研究的目的是进行系统评价和荟萃分析，以评估Sal B对抗肝纤维化的作用，这将有助于药物开发和临床研究的病理机制。
INPLASY202050101，于2020年5月28日注册。
